249 related articles for article (PubMed ID: 32511227)
1. MYO5B mutations in pheochromocytoma/paraganglioma promote cancer progression.
Tomić TT; Olausson J; Rehammar A; Deland L; Muth A; Ejeskär K; Nilsson S; Kristiansson E; Wassén ON; Abel F
PLoS Genet; 2020 Jun; 16(6):e1008803. PubMed ID: 32511227
[TBL] [Abstract][Full Text] [Related]
2. Malignant pheochromocytomas/paragangliomas harbor mutations in transport and cell adhesion genes.
Wilzén A; Rehammar A; Muth A; Nilsson O; Tešan Tomić T; Wängberg B; Kristiansson E; Abel F
Int J Cancer; 2016 May; 138(9):2201-11. PubMed ID: 26650627
[TBL] [Abstract][Full Text] [Related]
3. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
[TBL] [Abstract][Full Text] [Related]
4. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers.
de Cubas AA; Korpershoek E; Inglada-Pérez L; Letouzé E; Currás-Freixes M; Fernández AF; Comino-Méndez I; Schiavi F; Mancikova V; Eisenhofer G; Mannelli M; Opocher G; Timmers H; Beuschlein F; de Krijger R; Cascon A; Rodríguez-Antona C; Fraga MF; Favier J; Gimenez-Roqueplo AP; Robledo M
Clin Cancer Res; 2015 Jul; 21(13):3020-30. PubMed ID: 25825477
[TBL] [Abstract][Full Text] [Related]
5. Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma.
Buffet A; Zhang J; Rebel H; Corssmit EPM; Jansen JC; Hensen EF; Bovée JVMG; Morini A; Gimenez-Roqueplo AP; Hes FJ; Devilee P; Favier J; Bayley JP
J Clin Endocrinol Metab; 2021 Jan; 106(2):459-471. PubMed ID: 33180916
[TBL] [Abstract][Full Text] [Related]
6. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis.
Crona J; Lamarca A; Ghosal S; Welin S; Skogseid B; Pacak K
Endocr Relat Cancer; 2019 May; 26(5):539-550. PubMed ID: 30893643
[TBL] [Abstract][Full Text] [Related]
7. Mutational Profile and Potential Molecular Therapeutic Targets of Pheochromocytoma.
Ma X; Ling C; Zhao M; Wang F; Cui Y; Wen J; Ji Z; Zhang C; Chen S; Tong A; Li Y
Front Endocrinol (Lausanne); 2022; 13():921645. PubMed ID: 35966080
[TBL] [Abstract][Full Text] [Related]
8. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease.
Ogasawara T; Fujii Y; Kakiuchi N; Shiozawa Y; Sakamoto R; Ogawa Y; Ootani K; Ito E; Tanaka T; Watanabe K; Yoshida Y; Kimura N; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Ogawa S
J Clin Endocrinol Metab; 2022 Aug; 107(9):2545-2555. PubMed ID: 35730597
[TBL] [Abstract][Full Text] [Related]
9. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.
Calsina B; Currás-Freixes M; Buffet A; Pons T; Contreras L; Letón R; Comino-Méndez I; Remacha L; Calatayud M; Obispo B; Martin A; Cohen R; Richter S; Balmaña J; Korpershoek E; Rapizzi E; Deutschbein T; Vroonen L; Favier J; de Krijger RR; Fassnacht M; Beuschlein F; Timmers HJ; Eisenhofer G; Mannelli M; Pacak K; Satrústegui J; Rodríguez-Antona C; Amar L; Cascón A; Dölker N; Gimenez-Roqueplo AP; Robledo M
Genet Med; 2018 Dec; 20(12):1652-1662. PubMed ID: 30008476
[TBL] [Abstract][Full Text] [Related]
10. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
11. HRAS mutation prevalence and associated expression patterns in pheochromocytoma.
Stenman A; Welander J; Gustavsson I; Brunaud L; Bäckdahl M; Söderkvist P; Gimm O; Juhlin CC; Larsson C
Genes Chromosomes Cancer; 2016 May; 55(5):452-9. PubMed ID: 26773571
[TBL] [Abstract][Full Text] [Related]
12. Genetic bases of pheochromocytoma and paraganglioma.
Cascón A; Calsina B; Monteagudo M; Mellid S; Díaz-Talavera A; Currás-Freixes M; Robledo M
J Mol Endocrinol; 2023 Apr; 70(3):. PubMed ID: 36520714
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Expression is Linked to Tumor-Infiltrating T-Cell Exhaustion and Adverse Pathological Behavior in Pheochromocytoma/Paraganglioma.
Yu A; Xu X; Pang Y; Li M; Luo J; Wang J; Liu L
Lab Invest; 2023 Sep; 103(9):100210. PubMed ID: 37406931
[TBL] [Abstract][Full Text] [Related]
15. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
[TBL] [Abstract][Full Text] [Related]
16. Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.
Letellier E; Schmitz M; Ginolhac A; Rodriguez F; Ullmann P; Qureshi-Baig K; Frasquilho S; Antunes L; Haan S
Br J Cancer; 2017 Nov; 117(11):1689-1701. PubMed ID: 29024942
[TBL] [Abstract][Full Text] [Related]
17. Next-generation panel sequencing identifies
Gieldon L; Masjkur JR; Richter S; Därr R; Lahera M; Aust D; Zeugner S; Rump A; Hackmann K; Tzschach A; Januszewicz A; Prejbisz A; Eisenhofer G; Schrock E; Robledo M; Klink B
Eur J Endocrinol; 2018 Feb; 178(2):K1-K9. PubMed ID: 29158289
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of MYO5B promotes invasion and motility in gastric cancer cells.
Dong W; Chen X; Chen P; Yue D; Zhu L; Fan Q
Dig Dis Sci; 2012 May; 57(5):1247-52. PubMed ID: 22134786
[TBL] [Abstract][Full Text] [Related]
19. Loss-of-function of MYO5B is the main cause of microvillus inclusion disease: 15 novel mutations and a CaCo-2 RNAi cell model.
Ruemmele FM; Müller T; Schiefermeier N; Ebner HL; Lechner S; Pfaller K; Thöni CE; Goulet O; Lacaille F; Schmitz J; Colomb V; Sauvat F; Revillon Y; Canioni D; Brousse N; de Saint-Basile G; Lefebvre J; Heinz-Erian P; Enninger A; Utermann G; Hess MW; Janecke AR; Huber LA
Hum Mutat; 2010 May; 31(5):544-51. PubMed ID: 20186687
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
